ENDRA Life Sciences

104 articles about ENDRA Life Sciences

• ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

  3/28/2024

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update.

• ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

  3/21/2024

  ENDRA Life Sciences Inc. today announced that the company will report financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024 after the close of trading on the U.S. financial markets.

• New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System

  2/21/2024

  ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, welcomes the adoption of the ICD-10 K76.0 code for the diagnosis of Non-Alcoholic Fatty Liver Disease.

• ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

  2/14/2024

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces the issuance of three new patents, including one in the U.S., one in China and one in Europe.

• ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

  11/29/2023

  ENDRA Life Sciences Secures 39 th U.S. Patent for TAEUS ® System Technology.

• ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference

  11/27/2023

  ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference.

• ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

  11/14/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

• ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

  11/8/2023

  ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announces the issuance of three new patents, including one in the U.S. and two in China.

• ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023

  11/6/2023

  ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting ® 2023.

• Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

  9/7/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA) today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.

• ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

  8/30/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company's De Novo request for the TAEUS liver system has advanced to substantive review with the U.S. Food and Drug Administration (FDA).

• ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

  8/23/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe.

• ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

  8/14/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for the TAEUS system.

• ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

  8/14/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update.

• ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

  8/1/2023

  ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the three and six months ended June 30, 2023 on Monday, August 14, 2023 after the close of trading on the U.S. financial markets.

• ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023

  7/6/2023

  ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, announced its 2023 Annual Meeting of Stockholders, which was scheduled to be held this morning, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

• Study Highlighting ENDRA Life Sciences’ TAEUS Technology to be Presented at EASL International Liver Congress 2023

  6/7/2023

  ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced the acceptance of a poster titled “Thermoacoustic assessment of fatty liver disease - an early clinical feasibility study” for presentation at the International Liver Congress ™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place June 21-24 in Vienna, Austria.

• ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

  5/15/2023

  ENDRA Life Sciences Inc., a pioneer of Thermo Acoustic Enhanced UltraSound, reported financial results for the three months ended March 31, 2023 and provided a business update.

• ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023

  5/4/2023

  ENDRA Life Sciences Inc. today announced that the company will report financial results for the three months ended March 31, 2023 on Monday, May 15, 2023 after the close of trading on the U.S. financial markets.

• ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Securities

  5/2/2023

  ENDRA Life Sciences Inc. announced the closing of its previously announced underwritten public offering of 4,312,500 shares of its common stock and warrants to purchase 2,156,250 shares of its common stock, which included the exercise in full by the underwriter of its option to purchase 562,500 additional shares of ENDRA’s common stock and additional warrants to purchase 281,250 shares of common stock.